Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Gastrointestinal Bleeding Treatment Market

ID: MRFR/HC/29351-HCR
100 Pages
Rahul Gotadki
Last Updated: May 15, 2026

Gastrointestinal Bleeding Treatment Market Research Report By Drug Class (Vasopressin Agonists, Somatostatin Analogues, Proton Pump Inhibitors, H2 Receptor Antagonists, Antiplatelet Agents, Antifibrinolytic Agents), By Route of Administration (Intravenous, Oral, Endoscopic), By Indication (Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, Variceal Bleeding) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Gastrointestinal Bleeding Treatment Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.1.1 Proton Pump Inhibitors | |
      2. 4.1.2 Somatostatin Analogues | |
      3. 4.1.3 H2 Receptor Antagonists | |
      4. 4.1.4 Vasopressin Agonists | |
      5. 4.1.5 Antiplatelet Agents | |
      6. 4.1.6 Antifibrinolytic Agents |
    2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.2.1 Intravenous | |
      2. 4.2.2 Oral | |
      3. 4.2.3 Endoscopic |
    3. 4.3 Healthcare, BY Indication (USD Billion) | |
      1. 4.3.1 Upper Gastrointestinal Bleeding | |
      2. 4.3.2 Lower Gastrointestinal Bleeding | |
      3. 4.3.3 Variceal Bleeding |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Johnson & Johnson (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 AbbVie Inc. (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Boehringer Ingelheim (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Takeda Pharmaceutical Company Limited (JP) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Fresenius Kabi AG (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Amgen Inc. (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Merck & Co., Inc. (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Gilead Sciences, Inc. (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
    7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 US MARKET ANALYSIS BY INDICATION |
    9. 6.6 CANADA MARKET ANALYSIS BY DRUG CLASS |
    10. 6.7 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    11. 6.8 CANADA MARKET ANALYSIS BY INDICATION |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    14. 6.11 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    15. 6.12 GERMANY MARKET ANALYSIS BY INDICATION |
    16. 6.13 UK MARKET ANALYSIS BY DRUG CLASS |
    17. 6.14 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    18. 6.15 UK MARKET ANALYSIS BY INDICATION |
    19. 6.16 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    20. 6.17 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    21. 6.18 FRANCE MARKET ANALYSIS BY INDICATION |
    22. 6.19 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    23. 6.20 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    24. 6.21 RUSSIA MARKET ANALYSIS BY INDICATION |
    25. 6.22 ITALY MARKET ANALYSIS BY DRUG CLASS |
    26. 6.23 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    27. 6.24 ITALY MARKET ANALYSIS BY INDICATION |
    28. 6.25 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    29. 6.26 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    30. 6.27 SPAIN MARKET ANALYSIS BY INDICATION |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY DRUG CLASS |
    36. 6.33 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    37. 6.34 CHINA MARKET ANALYSIS BY INDICATION |
    38. 6.35 INDIA MARKET ANALYSIS BY DRUG CLASS |
    39. 6.36 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    40. 6.37 INDIA MARKET ANALYSIS BY INDICATION |
    41. 6.38 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    42. 6.39 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    43. 6.40 JAPAN MARKET ANALYSIS BY INDICATION |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY INDICATION |
    50. 6.47 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    51. 6.48 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    52. 6.49 THAILAND MARKET ANALYSIS BY INDICATION |
    53. 6.50 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    54. 6.51 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    55. 6.52 INDONESIA MARKET ANALYSIS BY INDICATION |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY INDICATION |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    61. 6.58 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    62. 6.59 BRAZIL MARKET ANALYSIS BY INDICATION |
    63. 6.60 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    64. 6.61 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    65. 6.62 MEXICO MARKET ANALYSIS BY INDICATION |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY INDICATION |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY INDICATION |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Proton Pump Inhibitors
  • Somatostatin Analogues
  • H2 Receptor Antagonists
  • Vasopressin Agonists
  • Antiplatelet Agents
  • Antifibrinolytic Agents

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Oral
  • Endoscopic

Healthcare By Indication (USD Billion, 2025-2035)

  • Upper Gastrointestinal Bleeding
  • Lower Gastrointestinal Bleeding
  • Variceal Bleeding

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions